Prediction of Treatment Failure Using 2010 World Health Organization Guidelines Is Associated With High Misclassification Rates and Drug Resistance Among HIV-Infected Cambodian Children
Open Access
- 26 April 2012
- journal article
- research article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 55 (3), 432-440
- https://doi.org/10.1093/cid/cis433
Abstract
Background. Antiretroviral therapy (ART) in resource-limited settings (RLSs) is monitored clinically and immunologically, according to World Health Organization (WHO) or national guidelines. Revised WHO pediatric guidelines were published in 2010, but their ability to accurately identify virological failure is unclear. Methods. We evaluated performance of WHO 2010 guidelines and compared them with WHO 2006 and Cambodia 2011 guidelines among children on ≥6 months of first-line ART at Angkor Hospital for Children between January 2005 and September 2010. We determined sensitivity, specificity, positive and negative predictive values, and accuracy using bootstrap resampling to account for multiple tests per child. Human immunodeficiency virus (HIV) resistance was compared between those correctly and incorrectly identified by each guideline. Results. Among 457 children with 1079 viral loads (VLs), 20% had >400 copies/mL. For children with WHO stage 1/2 HIV, misclassification as failure (met CD4 failure criteria, but VL undetectable) was 64% for WHO 2006 guidelines, 33% for WHO 2010 guidelines, and 81% for Cambodia 2011 guidelines; misclassification as success (did not meet CD4 failure, but VL detectable) was 11%, 12%, and 12%, respectively. For children with WHO stage 3/4 HIV, misclassification as failure was 35% for WHO 2006 guidelines, 40% for WHO 2010 guidelines, and 43% for Cambodia 2011 guidelines; misclassification as success was 13%, 24%, and 21%, respectively. Compared with WHO 2006 guidelines, WHO 2010 guidelines significantly increased the risk of misclassification as success in stage 3/4 HIV (P < .05). The WHO 2010 guidelines failed to identify 98% of children with extensive reverse-transcriptase resistance. Conclusions. In our cohort, lack of virological monitoring would result in unacceptable treatment failure misclassification, leading to premature ART switch and resistance accumulation. Affordable virological monitoring suitable for use in RLSs is desperately needed.Keywords
This publication has 31 references indexed in Scilit:
- Irreversible electroporation of the liver and liver hilum in swineHPB, 2011
- Virologic Failure and Second-Line Antiretroviral Therapy in Children in South Africa—The IeDEA Southern Africa CollaborationJAIDS Journal of Acquired Immune Deficiency Syndromes, 2011
- Early Virologic Failure and the Development of Antiretroviral Drug Resistance Mutations in HIV-Infected Ugandan ChildrenJAIDS Journal of Acquired Immune Deficiency Syndromes, 2011
- Pooling Strategies to Reduce the Cost of HIV-1 RNA Load Monitoring in a Resource-Limited SettingClinical Infectious Diseases, 2010
- Viral Load Predicts New World Health Organization Stage 3 and 4 Events in HIV‐Infected Children Receiving Highly Active Antiretroviral Therapy, Independent of CD4 T Lymphocyte ValueClinical Infectious Diseases, 2010
- Antiretroviral Treatment for Children with Peripartum Nevirapine ExposureThe New England Journal of Medicine, 2010
- High survival and treatment success sustained after two and three years of first‐line ART for children in CambodiaJournal of the International AIDS Society, 2010
- XVII International AIDS Conference: From Evidence to Action ‐ Basic scienceJournal of the International AIDS Society, 2009
- Excellent outcomes among HIV+ children on ART, but unacceptably high pre-ART mortality and losses to follow-up: a cohort study from CambodiaBMC Pediatrics, 2009
- Failure of immunologic criteria to appropriately identify antiretroviral treatment failure in UgandaAIDS, 2009